NCT03610711View on ClinicalTrials.gov

REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

March 6, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Gastroesophageal CancerImmune Checkpoint Inhibition
Interventions
DRUG

Nivolumab

240mg administered IV over 30 minutes every 2 weeks for one year

DRUG

Relatlimab

every 2 weeks for one year

Trial Locations (3)

15212

Alleghany Health Network, Pittsburgh

21287

Johns Hopkins University, Baltimore

75246

Baylor University, Dallas

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER